|
|
|
|
Fibrogen Inc (NASDAQ: FGEN) |
|
|
|
|
|
Fibrogen Inc's Suppliers Performance
FGEN's Supply Chain
| |
|
FGEN Costs vs Sales of Suppliers Growth |
Fibrogen Inc's cost of sales deteriorated by -99.02 % year on year, relative to one quarter ago cost of sales fell by -98.78 % in Q1.
•
More on FGEN Suppliers
|
|
|
Fibrogen Inc's cost of sales deteriorated by -99.02 % year on year, compare to one quarter ago cost of sales fell by -98.78 % in Q1.
•
More on FGEN Suppliers
|
Select the Relationship:
|
|
Select the Category:
|
|
Fibrogen Inc's Comment on Supply Chain
FGEN's vs. Suppliers, Data
(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)
| COMPANY NAME |
MARKET CAP |
REVENUES |
INCOME |
EMPLOYEES |
|
Fibrogen Inc
|
772.30 |
180.01 |
-10.01 |
333 |
| SUBTOTAL |
0.00 |
0.00 |
0.00 |
- |
News about
Fibrogen Inc Contracts
|
In recent announcements, FibroGen, Inc. has revealed significant advancements in the development of FG-3246, a potential innovative anti-CD46 antibody drug conjugate (ADC). These updates, ranging from positive interim results to the upcoming investor event, hold tremendous importance for FibroGen s position in the competitive pharmaceutical industry. This article aims to outline the key facts and assess their impact on the company. 1. Positive Interim Results from Phase 1b/2 Study:At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, FibroGen disclosed positive interim results from the dose escalation phase of a Phase 1b/2 study conducted by the University of California San Francisco. The ...
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
